Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › acarbose

acarbose

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of acarbose

8 trials tracked of acarbose: 7 in phase 3 or 4 and 3 with published results. The most-cited published study has 51 citations.

8Trials tracked
7Phase 3 & 4
0Recruiting
3With published results
Phase distribution
Phase 4 6 Phase 3 1 Phase 2 1
  1. Phase 4 Remission Evaluation of Metabolic Interventions in Type 2 Diabetes (REMIT Pilot Trial) Completed · 51 cited
  2. Phase 4 24-Week, Multicenter, Randomized, Parallel-group, Open-label, Active Controlled Phase IV Study to Assess the Efficacy, Safety and Tolerability of Saxagliptin Compared With Acarbose When in Combination With Metformin in Patients With T2D Inadequately Controlled With Metformin Monotherapy Completed · 23 cited
  3. Phase 4 A Study of the Safety and Efficacy of Glimepiride, Gliclazide, Repaglinide or Acarbose When Added to Sitagliptin + Metformin Combination Therapy in Chinese Participants With Diabetes (MK-0431-313) Completed · 14 cited
  4. Phase 4 Efficacy and Safety of Voglibose Compared With Acarbose in Participants With Type 2 Diabetes Completed
  5. Phase 4 Study to Evaluate the Efficacy of Acarbose,Metformin,Sitagliptin Combination Treatment in DM Patients Completed
  6. Phase 4 Effects of Nateglinide on Postprandial Glucose Excursion by Restoring Early Phase Insulin Secretion Completed
Show 2 more trials
  1. Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of the Addition of Sitagliptin in Participants With Type 2 Diabetes Mellitus Receiving Acarbose Monotherapy (MK-0431-130) Completed
  2. Phase 2 Acarbose Anti-aging Effects in Geriatric Subjects (Substudy B & C) Completed

Showing the 8 most-cited and recently-updated of 8 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Long-term voglibose use likely caused leukopenia in a 71-year-old man with type 2 diabetes
Diabetes & Endocrinology Sys. Review
Long-term voglibose use likely caused leukopenia in a 71-year-old man with type 2 diabetes Switching diabetes drugs reversed low white blood cell counts in a 71-year-old man
This case report describes a 71-year-old male with well-controlled type 2 diabetes who developed leukopenia after long-term voglibose use. W…
A 71-year-old man with type 2 diabetes saw his white blood cell count rise after switching from voglibose to acarbose, suggesting the first …
Frontiers Jun 4, 2026
Alpha-glucosidase inhibitors like acarbose show anti-virulence activity against Candida albicans in vitro
Infectious Disease Sys. Review
Alpha-glucosidase inhibitors like acarbose show anti-virulence activity against Candida albicans in vitro Could common diabetes drugs help stop fungal infections from building tough protective shields?
This systematic review evaluated alpha-glucosidase inhibitors, particularly acarbose, as selective antifungal inhibitors against Candida alb…
A common diabetes drug called acarbose may help break down the tough shields that hide dangerous fungal infections from treatment.
Frontiers Apr 14, 2026